BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $39
BTIG has reiterated its Buy rating on Denali Therapeutics (DNLI.US) and increased its price target to $39. This revised target reflects a positive outlook on the company's prospects.
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9% - Here's What Happened
Denali Therapeutics (NASDAQ:DNLI) shares dropped 4.9% during mid-day trading on Monday, with significantly lower than average trading volume. Despite the price dip, analysts maintain a "Moderate Buy" consensus rating with an average target price of $34.82, and several firms recently raised their price targets. The company exhibits strong liquidity and low debt but remains unprofitable, though its recent quarterly EPS beat estimates.
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda has terminated its eight-year partnership with Denali Therapeutics, returning rights to a dementia program, including the DNL593 asset, to Denali. This decision was based on strategic considerations, not efficacy or safety data. Denali plans to independently advance DNL593, a protein replacement therapy for frontotemporal dementia, which is currently in a Phase 1/2 study with data expected this year, following the recent FDA approval of Denali’s Hunter syndrome therapy, Avlayah.
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
Capricorn Fund Managers Ltd has taken a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 62,197 shares valued at approximately $1.03 million in the fourth quarter. Institutional ownership of Denali Therapeutics is high at 92.92%, with significant investments from other firms like Foresite Capital Management and Holocene Advisors. Despite recent insider sales by CEO Ryan J. Watts and Alexander O. Schuth, Wall Street analysts maintain a "Moderate Buy" rating for DNLI, with an average price target of $34.82, suggesting potential upside from its current share price of around $20.65.
Denali Regains Full Control Of DNL593 As It Advances Toward Key 2026 Readout
Denali Therapeutics has regained full rights to its investigational therapy DNL593 after Takeda ended their co-development agreement for strategic reasons. DNL593, a progranulin replacement candidate for GRN-related Frontotemporal Dementia, remains on track, with Phase 1/2 results expected by the end of 2026. Denali's TransportVehicle platform, which delivers progranulin to the brain, is crucial to the therapy's potential, and the company now has full control over its development and intellectual property.
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC significantly increased its stake in Denali Therapeutics Inc. during the fourth quarter of 2025, purchasing an additional 111,391 shares. This move brings their total holdings to 149,592 shares, valued at $2.47 million. Despite some insider selling, analysts maintain a "Moderate Buy" rating for Denali Therapeutics, with several brokers raising their price targets for the stock.
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc
Aberdeen Group plc significantly increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 82.6% in the fourth quarter, bringing its total ownership to 1.39% valued at $33.6 million. Other major institutional investors, such as Norges Bank, Holocene Advisors, and UBS Group AG, also substantially increased their holdings, indicating robust institutional confidence in the company. Denali Therapeutics, a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, currently holds a "Moderate Buy" consensus rating with a target price of $34.82, despite recent insider selling by executives.
DNLI Technical Analysis & Stock Price Forecast
The article provides a technical analysis of Denali Therapeutics Inc (DNLI), indicating a "Strong Buy" consensus based on aggregated technical signals. It details various indicators including RSI, MACD, and moving averages, along with key support and resistance levels. The analysis highlights that DNLI is trading above its 60-day and 200-day moving averages, suggesting a potentially bullish long-term trend.
Denali Regains DNL593 Rights After Takeda Collaboration Ends
Denali Therapeutics announced that Takeda Pharmaceutical will terminate their collaboration on DNL593, an investigational therapy for GRN-related frontotemporal dementia. Denali will regain full rights and intellectual property to DNL593 and plans to continue its development independently, with Phase 1/2 study results expected by late 2026. The decision is described as strategic and not data-driven, and previous interim data showed promising results with no significant safety signals.
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement for DNL593, effective June 2, 2026. This decision was based on Takeda's strategic considerations unrelated to the drug's efficacy or safety, returning full development and commercialization rights to Denali without further payments owed. Denali will now control the future of DNL593.
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug
Takeda Pharmaceutical Company Limited has terminated its collaboration agreement with Denali Therapeutics Inc. for the co-development and co-commercialization of DNL593, a drug for GRN-related frontotemporal dementia. Denali will regain full rights to the DNL593 program and plans to continue its independent clinical development, with Phase 1/2 study results expected by the end of 2026. Takeda's decision was based on strategic considerations and not on the drug's efficacy or safety data.
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Denali Therapeutics has regained full rights to its investigational therapy DNL593 for GRN-related Frontotemporal Dementia (FTD-GRN) after Takeda terminated their collaboration due to strategic considerations not related to efficacy or safety. Denali plans to continue the clinical development of DNL593, which uses its TransportVehicle™ technology to deliver progranulin to the brain, with Phase 1/2 study results expected by the end of 2026. This therapy addresses a significant unmet medical need for FTD, a common dementia in younger individuals with no currently approved treatments to slow its progression.
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Denali Therapeutics has regained full rights to its investigational therapy DNL593 for GRN-related Frontotemporal Dementia (FTD-GRN) after Takeda terminated their collaboration agreement due to strategic considerations, not efficacy or safety. Denali, confident in DNL593's scientific rationale and data, plans to continue its clinical development, with Phase 1/2 study results expected by the end of 2026. This therapy uses Denali's Protein TransportVehicle™ to deliver progranulin across the blood-brain barrier, offering a potential treatment for a disease with no currently approved therapies.
Takeda exits dementia drug pact, Denali targets trial data by 2026 end
Denali Therapeutics has regained full rights to its investigational therapy DNL593 for GRN-related Frontotemporal Dementia (FTD-GRN) after Takeda terminated their collaboration due to strategic considerations. Denali will continue the clinical development independently and expects to release Phase 1/2 results, including biomarker data, by the end of 2026. The company remains confident in the drug's potential, citing positive interim data showing dose-dependent progranulin increases and favorable tolerability.
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593
Denali Therapeutics Inc. announced the termination of its collaboration agreement with Takeda Pharmaceutical Company Limited for the co-development and co-commercialization of DNL593. Takeda's decision was strategic and not related to the drug's efficacy or safety. All rights for the DNL593 program will revert to Denali, and the company expects to release data from the ongoing Phase 1/2 study by the end of 2026.
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
The biopharma sector experienced significant M&A activity with Biogen, Eli Lilly, Merck, and Novartis collectively spending over $20 billion on acquisitions. Rare disease therapies saw three new FDA approvals for treatments from Denali Therapeutics, Rocket Pharmaceuticals, and Biogen. Meanwhile, Wave Life Sciences' stock value plummeted after its obesity candidate failed to impress investors in a Phase 1 trial.
Denali Therapeutics Secures $200 Million Royalty Funding
Denali Therapeutics received $200 million in gross proceeds from a synthetic royalty funding agreement with Royalty Pharma on March 27, 2026. This funding followed the FDA's accelerated approval of Denali’s drug tividenofusp alfa on March 24, 2026, providing significant non-dilutive capital and strengthening the company's position in the neurodegenerative disease therapeutics market. Despite mixed technicals and valuation challenges, analysts rate DNLI stock a Buy with a $41.00 price target, supported by the strong corporate catalyst of FDA approval.
Denali Therapeutics receives $200 million from royalty agreement after FDA approval
Denali Therapeutics Inc. received $200 million in gross proceeds from a synthetic royalty funding agreement with Royalty Pharma, following the FDA's accelerated approval of tividenofusp alfa. This approval, for the treatment of Hunter syndrome, has led several financial firms to raise their price targets for Denali. The drug is the first commercial product from Denali's Transport Vehicle platform.
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK
Denali Therapeutics Inc. has finalized its synthetic royalty funding agreement with Royalty Pharma, securing $200.0 million in gross proceeds on March 27, 2026. This closing was triggered by the U.S. FDA's accelerated approval of tividenofusp alfa on March 24, 2026. The funding provides significant immediate capital for Denali, strengthening its balance sheet, in exchange for a portion of future product-linked royalties on the approved asset.
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition?
Denali Therapeutics received accelerated FDA approval for AVLAYAH (tividenofusp alfa-eknm), its first brain-penetrant biologic, for treating Hunter syndrome. This approval validates Denali's TransportVehicle platform for delivering biologics across the blood-brain barrier. The company, currently pre-revenue and unprofitable, now faces execution challenges related to AVLAYAH's launch, real-world safety, and confirmatory studies, with its stock potentially overvalued despite the breakthrough.
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI)
Denali Therapeutics Inc. published a slide deck discussing the FDA approval and commercial launch plans for AVLAYAH, their treatment for Hunter Syndrome. This article from Seeking Alpha's transcripts team highlights the event, providing insights into Denali's upcoming product launch. The company aims to address the needs of patients with Hunter Syndrome following regulatory clearance.
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News
Goldman Sachs has reiterated its 'Buy' rating on Denali Therapeutics (DNLI) and increased the price target from $35 to $40, representing a 14.29% rise. This update follows several other analyst adjustments, including BTIG raising its target to $36 and Wolfe Research initiating coverage with a 'Peer Perform' rating. Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases, currently has an average target price of $35.13 from 15 analysts, implying a 70.63% upside from its current price, though GuruFocus estimates a significant downside based on its GF Value.
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI)
Vanguard has filed an amended Schedule 13G/A for Denali Therapeutics Inc. (DNLI), reporting zero beneficial ownership of DNLI common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries and business divisions will now report their beneficial ownership separately. The filing clarifies that Vanguard itself no longer holds nor is deemed to hold these shares, attributing the disaggregation to SEC Release No. 34-39538.
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Denali Therapeutics has received FDA approval for Avlayah, a new biologic drug designed to treat the neurologic manifestations of Hunter syndrome. This marks Denali's first commercial product and utilizes its proprietary TransportVehicle technology to cross the blood-brain barrier. The approval is a significant milestone for brain-penetrating drugs and provides a new treatment option for pediatric Hunter syndrome patients before irreversible neurologic impairment occurs.
Denali Receives FDA Approval for Hunter Syndrome Treatment, Shares Rise
Denali Therapeutics received FDA accelerated approval for Avlayah (tividenofusp alfa-eknm) to treat Hunter syndrome, marking the first new therapeutic option in nearly two decades for the rare disease. This approval, based on strong biomarker results showing a 91% reduction in CSF heparan sulfate levels, led to a 7.15% surge in Denali's stock price. Avlayah leverages Denali's TransportVehicle platform to cross the blood-brain barrier, highlighting the company's innovation in neurodegenerative and lysosomal storage disorders.
H.C. Wainwright raises Denali Therapeutics price target to $42
H.C. Wainwright has increased its price target for Denali Therapeutics Inc. (NASDAQ:DNLI) to $42 from $32, while reiterating a Buy rating, following the accelerated FDA approval of AVLAYAH for Hunter syndrome. This approval, which came ahead of schedule, is expected to cover a significant portion of MPS II patients and leverage an established commercial infrastructure. The firm also included DNL126 in its valuation, leading to the revised target, and the company's strong financial position and other analyst upgrades indicate growing confidence in its commercial prospects.
H.C. Wainwright raises Denali Therapeutics price target to $42
H.C. Wainwright increased its price target for Denali Therapeutics (NASDAQ: DNLI) to $42 from $32, maintaining a Buy rating after the FDA granted accelerated approval for AVLAYAH, a treatment for Hunter syndrome. This approval, which came three weeks early, led to a nearly 14% stock surge and reflects strong analyst confidence, with other firms also raising their price targets. The company's strong balance sheet and approval for a first-of-its-kind treatment highlight positive commercial prospects.
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
The FDA has granted accelerated approval to Denali Therapeutics' Avlayah (tividenofusp alfa-eknm), making it the first brain-penetrating biologic for Hunter syndrome, a rare genetic disorder. The approval is based on the drug's ability to significantly reduce a key disease biomarker and is supported by findings from a Phase 1/2 clinical trial. Denali also received a Rare Pediatric Disease Priority Review Voucher, while competitor REGENXBIO faced a setback for its similar drug RGX-121.
Some 13 years and $2 billion later, Denali Therapeutics wins first drug approval
Denali Therapeutics, a South San Francisco biotechnology company, has received its first drug approval after 13 years and a $2 billion investment. The approval is for a drug that utilizes a special transport technology capable of crossing the blood-brain barrier.
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics (Nasdaq: DNLI) has received accelerated FDA approval for AVLAYAH™ (tividenofusp alfa-eknm), an enzyme replacement therapy for Hunter syndrome (MPS II). This is the first FDA-approved biologic designed to cross the blood-brain barrier for this debilitating disease, marking the first new treatment option in nearly 20 years. The approval is based on a significant reduction in cerebrospinal fluid heparan sulfate levels and comes with a Rare Pediatric Disease Priority Review Voucher.
Denali approval revives surrogate-endpoint path in neuronal MPS
Denali Therapeutics Inc. received accelerated FDA approval for Avlayah tividenofusp alfa-eknm, an enzyme replacement therapy for Hunter syndrome, marking the company's first product and the first U.S. approval for a brain shuttle-enabled protein therapy. This approval, based on a biomarker (reduction of heparan sulfate in cerebrospinal fluid), suggests the FDA's continued acceptance of surrogate endpoints for severe rare diseases.
Oppenheimer raises Denali Therapeutics price target on FDA approval
Oppenheimer increased its price target for Denali Therapeutics Inc. (NASDAQ:DNLI) to $40 from $35, maintaining an Outperform rating. This adjustment follows the FDA's early approval of Denali's Hunter syndrome treatment, Avlayah, which also granted the company a priority review voucher. The approval marks a significant advancement as the first FDA-approved treatment for Hunter syndrome in nearly 20 years, leveraging Denali's innovative TransportVehicle platform to cross the blood-brain barrier.
FDA approves Denali Therapeutics drug for Hunter syndrome
The FDA has approved Denali Therapeutics' drug Avlayah for Hunter syndrome, a notable decision given the agency's recent stricter stance on rare disease drugs. This approval comes after the FDA had previously rejected a Hunter syndrome gene therapy from Regenxbio, requiring more clinical data. The approval of Avlayah was highly anticipated, especially after concerns arose among advocates regarding the fate of Denali's drug following other recent rejections of rare disease therapies.
US FDA approves Denali's genetic disorder therapy for children
The U.S. Food and Drug Administration has approved Denali Therapeutics' Avlayah, an enzyme replacement therapy, for treating children with Hunter syndrome, a rare genetic disorder. This marks Denali's first regulatory approval in the U.S., but continued approval is contingent on a confirmatory trial. The therapy, priced at $5,200 per vial, targets neurologic symptoms and was approved based on a surrogate endpoint measuring the reduction of heparan sulfate.
Denali Therapeutics Receives FDA Approval for AVLAYAH™, First New Treatment for Hunter Syndrome in Nearly 20 Years
Denali Therapeutics has received FDA accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first new treatment for Hunter syndrome in nearly 20 years. This enzyme replacement therapy is designed to cross the blood-brain barrier to treat neurological symptoms in pediatric patients with Hunter syndrome. The approval is based on significant reduction of a disease biomarker in clinical trials, with ongoing studies to confirm long-term clinical benefits.
Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii)
Denali Therapeutics has announced that the U.S. FDA has approved Avlayah™ (Tividenofusp Alfa-Eknm) for the treatment of Hunter Syndrome (MPS II). This news was reported by Reuters and is considered a significant development for the company and patients with this condition.
Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ)
Denali Therapeutics (DNLI) saw a significant premarket stock increase following FDA approval of its lead candidate, tividenofusp alfa. This approval is for the treatment of Hunter syndrome, a rare genetic disorder. The news led to a roughly 9% gain in the company's stock.
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals
The Amyotrophic Lateral Sclerosis (ALS) market is projected for strong growth through 2034, with a market size of approximately $1 billion in 2023 across the 7MM. This outlook is supported by a robust pipeline of emerging therapies and key regulatory milestones, including FDA approvals and designations for several investigational treatments from companies like Amylyx Pharmaceuticals, Coya Therapeutics, and Neurizon Therapeutics. The report highlights significant market drivers such as rising ALS prevalence, increased investment in neurodegenerative disease research, and advancements in gene and RNA-based therapies, while also addressing barriers like high treatment costs and challenges in early diagnosis.
Price-Driven Insight from (DNLI) for Rule-Based Strategy
This article provides a price-driven analysis for Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models, suggesting weak near-term sentiment but long-term strength. It details specific trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis highlights an exceptional 40.8:1 risk-reward setup, targeting a 12.5% gain versus 0.3% risk.
1,000,000 Shares in Denali Therapeutics Inc. $DNLI Purchased by Foresite Capital Management VI LLC
Foresite Capital Management VI LLC recently acquired 1,000,000 shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the third quarter, a new stake valued at approximately $14,520,000. This investment represents 5.6% of Foresite Capital's holdings and makes Denali Therapeutics its 6th largest position. Other institutional investors like Norges Bank and UBS Group AG also increased their stakes in the biopharmaceutical company.
250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC
Boxer Capital Management LLC acquired 250,000 shares of Denali Therapeutics Inc. ($DNLI) during Q3, a new stake valued at approximately $3.63 million, making it 1.2% of Boxer's portfolio and giving them a 0.17% ownership in Denali. Other institutions like Norges Bank and UBS also increased their holdings, with institutional investors and hedge funds now owning 92.92% of Denali's stock. The company has a current market cap of $3.26 billion, and analysts maintain a "Moderate Buy" rating with a consensus price target of $32.20, despite recent insider share sales.
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA)
Two healthcare companies, Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA), have received bullish sentiments from analysts. Mayank Mamtani of B. Riley Securities reiterated a Buy rating for Denali Therapeutics with a $30.00 price target, while Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics with a target of $71.00. Both companies currently hold a "Strong Buy" consensus rating from analysts, indicating significant upside potential.
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
Denali Therapeutics (DNLI) has seen an 11.8% stock gain in the last month, outperforming its industry, sector, and the S&P 500 Index, largely due to investor optimism regarding the potential FDA approval of its lead candidate, tividenofusp alfa, for Hunter syndrome by April 5, 2026. The company also boasts a promising pipeline, including treatments for Sanfilippo syndrome type A and Alzheimer’s disease, supported by strategic partnerships. While valuation suggests it's currently undervalued and loss estimates are narrowing, prospective investors are advised to wait for the regulatory decision on DNL310 before investing, though current shareholders may consider holding.
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock?
Denali Therapeutics (DNLI) shares have risen 11.8% in the past month, outperforming the industry and S&P 500, primarily due to investor confidence in its Hunter syndrome drug candidate, tividenofusp alfa, which awaits FDA approval by April 5, 2026. The company boasts a robust pipeline and strategic partnerships, with analysts narrowing loss estimates, suggesting an undervalued stock. Denali's short-term performance hinges on regulatory approvals and pipeline progress.
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock?
Denali Therapeutics (DNLI) shares have surged 11.8% over the past month, outperforming its industry and the S&P 500, largely due to confidence in its lead candidate, tividenofusp alfa, for Hunter syndrome, awaiting FDA approval by April 5, 2026. The company boasts a robust pipeline and strategic partnerships, with analysts narrowing loss estimates, suggesting undervaluation despite short-term reliance on regulatory outcomes. While a "Hold" recommendation is given, approval of DNL310 could significantly enhance its commercial prospects and market position.
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts
Denali Therapeutics Inc. (NASDAQ:DNLI) has received a consensus "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $32.20. Despite this, CEO Ryan J. Watts and Alexander O. Schuth recently sold a significant number of shares. Institutional investors, however, have increased their holdings, with institutional ownership now around 92.9%.
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration
Denali Therapeutics (DNLI) recently reported wider losses for Q4 and full-year 2025 and filed a new US$200.7 million shelf registration for common stock, raising concerns about dilution and funding needs. While the stock has seen positive momentum over the longer term, its 3.1x price-to-book ratio appears expensive compared to the broader US biotech industry, though lower than some peers. Despite this, a discounted cash flow model suggests the shares may be undervalued, trading at a 17% discount to estimated fair value.
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date
Denali Therapeutics Inc. is reportedly progressing positively with the FDA regarding an action date for their Hunter drug. The article, published on March 10, 2026, details this development within the pharmaceutical industry. This news is relevant for those following rare diseases and the companies involved in their treatment.
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum
Denali Therapeutics Inc. (DNLI) is awaiting an imminent FDA decision for its novel Hunter syndrome therapy, tividenofusp alfa, supported by strong biomarker and clinical data. The company is pursuing robust commercial and pipeline strategies, utilizing its brain delivery platform and recent financing to expand into various rare and neurodegenerative diseases. This information is based on an AI-generated summary of Denali's Leerink Global Healthcare Conference 2026 Audio Transcript from March 9, 2026.
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
Several biopharmaceutical companies experienced significant stock gains on Monday. Relmada Therapeutics surged after releasing positive interim data from a Phase 2 trial. Hims & Hers Health also saw a substantial jump due to a collaboration with Novo Nordisk for weight-loss drugs and the settlement of a patent suit, while Xenon Pharmaceuticals reported positive Phase 3 results for a seizure treatment.
